Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
June 7, 2016
- PDUFA Date for Naldemedine Set for March 23, 2017
June 7, 2016
- Takecab Most Promoted Drug for 4 Months on End: Anterio
June 7, 2016
- FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
June 6, 2016
- Eisai, Novartis to Join Forces in US Lenvima Promotion for Kidney Cancer
June 6, 2016
- Astellas to Kick Off Global PIII on Xtandi for Triple-Negative Breast Cancer
June 6, 2016
- 27 Japan Drug Makers Derive Record 45.8% of Sales from Overseas Market: Jiho Tally
June 3, 2016
- AbbVie, EA Pharma Initiate Copromotion of Humira in GI Field
June 3, 2016
- Terano Tapped as President of Japan Vaccine
June 2, 2016
- Chugai Licenses Antibody SA237 to Roche, Japan Filing Slated for 2018
June 2, 2016
- Ex-Boehringer Japan Pres. Torii to Head Novartis Holdings Japan
June 2, 2016
- After Tax Hike Delay, Industry Officials Vigilant about Price Slash for Innovative Drugs
June 2, 2016
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
June 1, 2016
- Daiichi Sankyo Ceases Development of Patritumab for NSCLC
June 1, 2016
- Oncolys Concludes Option Agreement with US CRO for HIV Treatment Censavudine
June 1, 2016
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…